homoharringtonine + cytarabine + amsacrine

The combination of homoharringtonine, cytarabine, and amsacrine, commonly referred to as the **HAC regimen**, is a chemotherapy protocol primarily utilized in China for the treatment of hematological malignancies. **Homoharringtonine** (HHT), a natural alkaloid derived from the *Cephalotaxus* genus, acts as a protein synthesis inhibitor by binding to the A-site of the 60S ribosomal subunit and preventing the initial step of translation. **Cytarabine** (Ara-C) is a pyrimidine analog antimetabolite that interferes with DNA synthesis by inhibiting DNA polymerase. **Amsacrine** (AMSA) is an acridine derivative that functions as a topoisomerase II inhibitor, inducing DNA double-strand breaks and subsequent apoptosis. While the HAC regimen is a recognized salvage or induction therapy for refractory or relapsed **acute myeloid leukemia (AML)**, institutions such as the **2nd Affiliated Hospital of Guangzhou University of Chinese Medicine** (Guangdong Provincial Hospital of Chinese Medicine) have explored its components in broader contexts. Although traditionally an oncology protocol, the provided context suggests investigation into its potential application in inflammatory skin conditions like **atopic dermatitis**, possibly through low-dose or topical formulations aimed at modulating immune responses.

Other names

HHT + Ara-C + AMSA